Clinical Trials
4
Active:1
Completed:0
Trial Phases
3 Phases
Phase 1:1
Phase 3:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (50.0%)Not Applicable
1 (25.0%)Phase 1
1 (25.0%)OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Not Applicable
Recruiting
- Conditions
- Ovarian Neoplasm EpithelialFallopian Tube NeoplasmsOvarian Endometrioid CarcinomaHigh-grade Serous Ovarian Carcinoma (HGSOC)
- Interventions
- Other: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Swiss GO Trial Group
- Target Recruit Count
- 60
- Registration Number
- NCT06466382
- Locations
- 🇨🇭
Kantonsspital Baden AG, Baden, Aargau, Switzerland
🇨🇭HOCH Health Ostschweiz Kantonsspital St.Gallen, St Gallen, Saint Gallen, Switzerland
🇨🇭Thurgau AG Frauenfeld / Münsterlingen, Frauenfeld, Thurgau, Switzerland
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3
Recruiting
- Conditions
- Ovarian Neoplasm EpithelialLow-grade Serous Ovarian Carcinoma (LGSOC)Ovarian Endometrioid CarcinomaFallopian Tube NeoplasmsHigh-grade Serous Ovarian Carcinoma (HGSOC)Peritoneal Neoplasms
- Interventions
- Other: Placebo
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Swiss GO Trial Group
- Target Recruit Count
- 540
- Registration Number
- NCT04111978
- Locations
- 🇦🇹
Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria
🇦🇹Medizinische Universität Graz, Graz, Austria
🇦🇹Medizinische Universität Innsbruck, Innsbruck, Austria
News
No news found